Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
57.33
+1.03 (1.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.89B in the quarter ending September 30, 2024, with 8.44% growth. This brings the company's revenue in the last twelve months to $47.44B, up 5.56% year-over-year. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, down -2.50%.
Revenue (ttm)
$47.44B
Revenue Growth
+5.56%
P/S Ratio
2.45
Revenue / Employee
$1,391,056
Employees
34,100
Market Cap
116.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Cigna Group | 229.75B |
Elevance Health | 174.02B |
Pfizer | 59.38B |
Sanofi | 54.03B |
Medtronic | 33.00B |
Amgen | 32.53B |
Gilead Sciences | 28.30B |
Stryker | 21.97B |
BMY News
- 1 day ago - Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects - Seeking Alpha
- 1 day ago - Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued - Seeking Alpha
- 2 days ago - Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer - Business Wire
- 2 days ago - Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025 - Business Wire
- 2 days ago - BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program - PRNewsWire
- 2 days ago - Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare - PRNewsWire
- 3 days ago - Bristol-Myers: Still An Opportunity Yielding Over 4% - Seeking Alpha
- 4 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga